38552085|t|Severe hyponatremia and diabetes insipidus caused by low-dose cyclophosphamide in breast cancer patients: A case report and literature review.
38552085|a|RATIONALE: Cyclophosphamide (CTX) is widely used in the treatment of malignancies and autoimmune diseases. Although severe hyponatremia caused by low-dose CTX chemotherapy is uncommon, it can lead to serious complications and even death. PATIENT CONCERNS: A 44-year-old woman with left-sided breast cancer suddenly experienced headaches, disorientation and weakness after receiving low-dose neoadjuvant chemotherapy combined with CTX and doxorubicin. DIAGNOSES: The patient pathology showed invasive breast carcinoma. She developed severe hyponatremia and a generalized seizure after completing the first cycle of neoadjuvant chemotherapy with CTX and doxorubicin. Laboratory tests showed a serum sodium of 118 mmol/L (normal range 135-145 mmol/L) and potassium sodium 3.16 mmol/L (normal range 3.5-5.5 mmol/L). Subsequently, the patient developed secondary diabetes insipidus 4 hours after sodium supplementation, her 24-hour urine volume was 4730 mL (normal range 1000-2000 mL/24 hours), and the urine specific gravity decreased to 1.005. INTERVENTIONS: The patient was given intravenous sodium chloride (500 mL of 3%NaCl, 100 mL/hour) and potassium chloride (500 mL of 0.3%KCl, 250 mL/hour). Meanwhile, she was advised to reduce her water intake, and pituitrin was administered to prevent dehydration caused by diabetes insipidus. OUTCOMES: The patient completely recovered after correcting of the serum sodium concentration (137 mmol/L) without any neurological deficits. After discontinuing pituitrin, her 24-hour urine volume was 2060 mL and the urine specific gravity was 1.015. LESSONS: This is a typical case of severe hyponatremia induced by low-dose CTX. Clinicians and healthcare providers should be aware of this potential toxicity, and appropriate monitoring should be implemented.
38552085	7	19	hyponatremia	Disease	MESH:D007010
38552085	24	42	diabetes insipidus	Disease	MESH:D003919
38552085	62	78	cyclophosphamide	Chemical	MESH:D003520
38552085	82	95	breast cancer	Disease	MESH:D001943
38552085	96	104	patients	Species	9606
38552085	154	170	Cyclophosphamide	Chemical	MESH:D003520
38552085	172	175	CTX	Chemical	MESH:D003520
38552085	212	224	malignancies	Disease	MESH:D009369
38552085	229	248	autoimmune diseases	Disease	MESH:D001327
38552085	266	278	hyponatremia	Disease	MESH:D007010
38552085	298	301	CTX	Chemical	MESH:D003520
38552085	374	379	death	Disease	MESH:D003643
38552085	413	418	woman	Species	9606
38552085	435	448	breast cancer	Disease	MESH:D001943
38552085	470	479	headaches	Disease	MESH:D006261
38552085	481	495	disorientation	Disease	MESH:D003221
38552085	500	508	weakness	Disease	MESH:D018908
38552085	573	576	CTX	Chemical	MESH:D003520
38552085	581	592	doxorubicin	Chemical	MESH:D004317
38552085	594	603	DIAGNOSES	Disease	MESH:D065886
38552085	609	616	patient	Species	9606
38552085	634	659	invasive breast carcinoma	Disease	MESH:D001943
38552085	682	694	hyponatremia	Disease	MESH:D007010
38552085	713	720	seizure	Disease	MESH:D012640
38552085	787	790	CTX	Chemical	MESH:D003520
38552085	795	806	doxorubicin	Chemical	MESH:D004317
38552085	840	846	sodium	Chemical	MESH:D012964
38552085	895	911	potassium sodium	Chemical	-
38552085	973	980	patient	Species	9606
38552085	991	1019	secondary diabetes insipidus	Disease	MESH:D003919
38552085	1034	1040	sodium	Chemical	MESH:D012964
38552085	1203	1210	patient	Species	9606
38552085	1233	1248	sodium chloride	Chemical	MESH:D012965
38552085	1285	1303	potassium chloride	Chemical	MESH:D011189
38552085	1397	1406	pituitrin	Chemical	MESH:D010909
38552085	1435	1446	dehydration	Disease	MESH:D003681
38552085	1457	1475	diabetes insipidus	Disease	MESH:D003919
38552085	1491	1498	patient	Species	9606
38552085	1550	1556	sodium	Chemical	MESH:D012964
38552085	1596	1617	neurological deficits	Disease	MESH:D009461
38552085	1639	1648	pituitrin	Chemical	MESH:D010909
38552085	1771	1783	hyponatremia	Disease	MESH:D007010
38552085	1804	1807	CTX	Chemical	MESH:D003520
38552085	1879	1887	toxicity	Disease	MESH:D064420
38552085	Positive_Correlation	MESH:D003520	MESH:D007010
38552085	Negative_Correlation	MESH:D004317	MESH:D006261
38552085	Negative_Correlation	MESH:D010909	MESH:D003681
38552085	Positive_Correlation	MESH:D012964	MESH:D003919
38552085	Negative_Correlation	MESH:D003520	MESH:D001327
38552085	Positive_Correlation	MESH:D003520	MESH:D006261
38552085	Positive_Correlation	MESH:D003520	MESH:D003919
38552085	Negative_Correlation	MESH:D004317	MESH:D001943
38552085	Positive_Correlation	MESH:D003520	MESH:D012640
38552085	Negative_Correlation	MESH:D003520	MESH:D009369
38552085	Positive_Correlation	MESH:D004317	MESH:D003221
38552085	Positive_Correlation	MESH:D003520	MESH:D003221
38552085	Comparison	MESH:D003520	MESH:D004317
38552085	Negative_Correlation	MESH:D012965	MESH:D012640
38552085	Negative_Correlation	MESH:D003520	MESH:D001943
38552085	Negative_Correlation	MESH:D010909	MESH:D003919
38552085	Positive_Correlation	MESH:D004317	MESH:D007010
38552085	Positive_Correlation	MESH:D004317	MESH:D012640

